Low neutrophil-to-lymphocyte ratio and pan-immune-inflammation-value predict nodal pathologic complete response in 1274 breast cancer patients treated with neoadjuvant chemotherapy: a multicenter analysis.
axillary dissection
axillary surgery
breast cancer
inflammatory markers
neutrophil–lymphocyte ratio
pan-immune-inflammation value
sentinel lymph node biopsy
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2023
2023
Historique:
received:
23
05
2023
accepted:
24
07
2023
medline:
18
9
2023
pubmed:
18
9
2023
entrez:
18
9
2023
Statut:
epublish
Résumé
Systemic inflammatory markers draw great interest as potential blood-based prognostic factors in several oncological settings. The aim of this study is to evaluate whether neutrophil-to-lymphocyte ratio (NLR) and pan-immune-inflammation value (PIV) predict nodal pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in node-positive (cN+) breast cancer (BC) patients. Clinically, cN+ BC patients undergoing NAC followed by breast and axillary surgery were enrolled in a multicentric study from 11 Breast Units. Pretreatment blood counts were collected for the analysis and used to calculate NLR and PIV. Logistic regression analyses were performed to evaluate independent predictors of nodal pCR. A total of 1274 cN+ BC patients were included. Nodal pCR was achieved in 586 (46%) patients. At multivariate analysis, low NLR [odds ratio (OR) = 0.71; 95% CI, 0.51-0.98; This study found that low NLR and PIV levels predict axillary pCR in patients with BC undergoing NAC. Eudract number NCT05798806.
Sections du résumé
Background
UNASSIGNED
Systemic inflammatory markers draw great interest as potential blood-based prognostic factors in several oncological settings.
Objectives
UNASSIGNED
The aim of this study is to evaluate whether neutrophil-to-lymphocyte ratio (NLR) and pan-immune-inflammation value (PIV) predict nodal pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in node-positive (cN+) breast cancer (BC) patients.
Design
UNASSIGNED
Clinically, cN+ BC patients undergoing NAC followed by breast and axillary surgery were enrolled in a multicentric study from 11 Breast Units.
Methods
UNASSIGNED
Pretreatment blood counts were collected for the analysis and used to calculate NLR and PIV. Logistic regression analyses were performed to evaluate independent predictors of nodal pCR.
Results
UNASSIGNED
A total of 1274 cN+ BC patients were included. Nodal pCR was achieved in 586 (46%) patients. At multivariate analysis, low NLR [odds ratio (OR) = 0.71; 95% CI, 0.51-0.98;
Conclusion
UNASSIGNED
This study found that low NLR and PIV levels predict axillary pCR in patients with BC undergoing NAC.
Registration
UNASSIGNED
Eudract number NCT05798806.
Identifiants
pubmed: 37720495
doi: 10.1177/17588359231193732
pii: 10.1177_17588359231193732
pmc: PMC10504832
doi:
Banques de données
ClinicalTrials.gov
['NCT05798806']
Types de publication
Journal Article
Langues
eng
Pagination
17588359231193732Informations de copyright
© The Author(s), 2023.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest.
Références
J BUON. 2020 Jan-Feb;25(1):182-187
pubmed: 32277630
BMJ Open. 2021 Sep 24;11(9):e047957
pubmed: 34561257
J Clin Oncol. 2005 Dec 20;23(36):9304-11
pubmed: 16361629
Eur J Cancer. 2009 Sep;45(13):2284-92
pubmed: 19464164
Sci Rep. 2021 Jul 19;11(1):14662
pubmed: 34282214
Front Oncol. 2022 Feb 11;11:827625
pubmed: 35223459
Nat Immunol. 2018 Nov;19(11):1236-1247
pubmed: 30323345
Medicine (Baltimore). 2022 Jul 15;101(28):e29887
pubmed: 35839045
Medicine (Baltimore). 2020 May 29;99(22):e20346
pubmed: 32481414
Ann Surg Oncol. 2013 Jul;20(7):2227-35
pubmed: 23456316
Ann Surg Oncol. 2009 Mar;16(3):687-96
pubmed: 19101768
JAMA. 2013 Oct 9;310(14):1455-61
pubmed: 24101169
Ann Transl Med. 2023 Mar 15;11(5):218
pubmed: 37007543
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Clin Oncol. 2014 Sep 20;32(27):2959-66
pubmed: 25071121
J Clin Oncol. 2015 Jan 20;33(3):258-64
pubmed: 25452445
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Clin Oncol. 2005 Jun 1;23(16):3676-85
pubmed: 15738535
Oncotarget. 2016 Jan 26;7(4):5074-87
pubmed: 26506242
Ann Surg Oncol. 2012 Oct;19(10):3177-84
pubmed: 22772869
Breast Cancer Res Treat. 2019 Jan;173(2):343-352
pubmed: 30343457
Cancers (Basel). 2020 Apr 13;12(4):
pubmed: 32295078
Bull Cancer. 2023 Jun;110(6):605-615
pubmed: 37080848
Front Oncol. 2023 Mar 29;13:1167912
pubmed: 37064127
Front Oncol. 2023 Apr 03;13:1093155
pubmed: 37077821
Breast. 2019 Apr;44:33-38
pubmed: 30611095
Cancers (Basel). 2021 Apr 19;13(8):
pubmed: 33921727
Br J Cancer. 2021 Jan;124(2):359-367
pubmed: 32929195
Lancet Oncol. 2013 Jun;14(7):609-18
pubmed: 23683750
Br J Surg. 2022 Aug 16;109(9):857-863
pubmed: 35766257
Clin Breast Cancer. 2020 Dec;20(6):e675-e681
pubmed: 32653471
PLoS One. 2014 Dec 12;9(12):e115103
pubmed: 25501357
J Clin Oncol. 2011 Jul 1;29(19):2619-27
pubmed: 21606424
Arch Gynecol Obstet. 2023 Apr;307(4):1105-1113
pubmed: 35980458
Am J Surg. 2016 Nov;212(5):969-981
pubmed: 27671032
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
JAMA Oncol. 2015 Jul;1(4):448-54
pubmed: 26181252
Br J Cancer. 2020 Aug;123(3):403-409
pubmed: 32424148
Cancer. 2010 Jun 15;116(12):2884-9
pubmed: 20564395
Br J Surg. 2022 Nov 22;109(12):1206-1215
pubmed: 36130112
J Natl Cancer Inst. 2019 Jan 1;111(1):69-77
pubmed: 29788230
Breast Cancer. 2015 Nov;22(6):586-95
pubmed: 24574277
Breast. 2021 Dec;60:131-137
pubmed: 34624755